Xeris Pharmaceuticals (id:8127 XERS)
3.09 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 2:55:45 PM)
Exchange closed, opens in 18 hours 34 minutes
About Xeris Pharmaceuticals
Market Capitalization 453.21M
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| Headquarters (address) |
180 North LaSalle Street Chicago 60601 IL United States |
| Phone | 844 445 5704 |
| Website | https://www.xerispharma.com |
| Employees | 377 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | XERS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.69 - 3.64 |
| Market Capitalization | 453.21M |
| P/E trailing | -6.87 |
| P/E forward | -13.82 |
| Price/Sale | 2.42 |
| Price/Book | -16.26 |
| Beta | 1.28 |
| EPS | -0.430 |
| EPS United States (ID:6, base:3402) | 24.22 |